[Efficacy of WT1 peptide-/MUC-1 peptide-pulsed dendritic cell therapy in 313 patients with a wide range of cancers].

We assessed the efficacy of Wilms' tumor protein-1(WT1)peptide and/or mucin 1(MUC-1)peptide-pulsed dendritic cell(DC)therapy for a wide range of advanced cancers.This retrospective study included 313 patients with advanced cancer who were vaccinated ≥5 times in our clinic between May 2009 and October 2013.T he clinical response was evaluated.This treatment was approved by the ethics panel of our institution.A total of 313 patients were injected an average of 6.0 times with DCs(2.4×10 / 7 cells/injection).Overall, 292 of the 313(93%)patients obtained clinical benefit according to the Response Evaluation Criteria in Solid Tumors(RECIST), version 1.1. The median survival time(MST)from diagnosis and from first being admitted to this institution was 28.4 months and 13.2 months, respectively. Complete response(CR)was achieved in 21 patients(7.2%).Partial response(PR)was achieved in 69 patients(24%).Stable disease(SD)was observed in 107 patients(37%), and progressive disease(PD)was observed in 95 patients(33%).The response rate(RR)and disease control rate(DCR)for each type of cancer were as follows: colorectal cancer(56 patients), 25%and 45%, respectively; lung cancer(39 patients), 31% and 82%, respectively; pancreatic cancer(36 patients), 22% and 64%, respectively; gastric cancer( 34 patients), 32% and 74%; breast cancer(20 patients), 15% and 75%, respectively; ovarian cancer(16 patients), 19% and 50%, respectively; esophageal cancer(15 patients), 20% and 73%, respectively; and others(76 patients), 38% and 67%.These results demonstrated the potential clinical effectiveness of DC-based immunotherapy.